Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Heron Therapeuti(HRTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HRTX
11/10/2026: HRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Heron Therapeutics is a commercial-stage biotechnology company focused on delivering non-opioid pain management and oncology supportive care products. Its primary strength lies in its proprietary, FDA-approved assets like ZYNRELEF, which target significant gaps in postsurgical recovery. The company's growth story hinges on its ability to drive hospital adoption and expand market access for its specialized portfolio. However, Heron faces significant risks, including intense competition from large pharmaceutical players, high operating expenses, and the ongoing challenge of achieving sustained profitability. The stock may suit growth-oriented investors with high risk tolerance who are looking for potential upside from product scaling; investors should monitor quarterly sales volumes and new clinical developments closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth potential exists, but the company must demonstrate consistent commercial scaling to justify a long-term growth thesis. |
| Momentum investor | Strong fit while signal remains positive | The stock can exhibit high sensitivity to regulatory news or quarterly sales surprises, creating windows for momentum traders. |
| Value investor | Weak fit | The lack of consistent profitability and negative earnings make it unsuitable for traditional value-based investment strategies. |
| Dividend investor | Weak fit | Heron does not pay dividends and is focused on capital-intensive drug development and commercial growth. |
| Low-risk investor | Weak fit | The high volatility and clinical/regulatory risks make this stock inappropriate for low-risk, capital-preservation portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical, regulatory, and market sentiment shifts, leading to significant price swings. |
| Valuation risk | Medium / high | Valuations are often based on future growth assumptions rather than current earnings, creating risk if milestones are missed. |
| Competition risk (Pharmaceutical incumbents) | High | Heron faces significant competition from large, well-resourced pharmaceutical companies with established market presence. |
| Business quality | Medium | While the product pipeline has merit, the company's financial health is currently fragile due to persistent operating losses. |
| Dividend income | Low / none | Investors should not expect any income yield from this investment. |
| Execution risk | High | The ability to successfully market and achieve broad hospital adoption for ZYNRELEF and other products is critical to survival. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -4.04% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.36M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 6.9M shares | Beta 1.65 | 52 Weeks Range 0.26 - 1.57 | Updated Date 11/10/2026 |
52 Weeks Range 0.26 - 1.57 | Updated Date 11/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.11 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Acute Care & Oncology Products | Revenue generated from the sale of ZYNRELEF, CINVETI, and APONVIE to hospitals, clinics, and pharmacies. | Heron relies almost entirely on the successful sales and hospital adoption of its few specialized pharmaceutical products. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 46.95 | Enterprise Value 160.91M | Price to Sales(TTM) 0.47 |
Enterprise Value 160.91M | Price to Sales(TTM) 0.47 | ||
Enterprise Value to Revenue 1.06 | Enterprise Value to EBITDA 49.68 | Shares Outstanding 189.85M | Shares Floating 146.40M |
Shares Outstanding 189.85M | Shares Floating 146.40M | ||
Percent Insiders 1.05 | Percent Institutions 68.33 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.